{"filing":{"accession_number":"0001110803-26-000138","cik":"0001110803","ticker":"ILMN","company_name":"ILLUMINA, INC.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"ilmn-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/ilmn-20260616.htm"},"events":[{"id":13051,"run_id":11578,"accession_number":"0001110803-26-000138","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R\u0026D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.","company_name":"ILLUMINA, INC.","ticker":"ILMN","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10085,"accession_number":"0001110803-26-000138","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R\u0026D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T13:09:36.887556+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10085,"accession_number":"0001110803-26-000138","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R\u0026D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T13:09:36.887556+00:00","company_name":"ILLUMINA, INC.","ticker":"ILMN","filing_date":"2026-06-23"}]}